MacroGenics, Inc. Common Stock MGNX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-16T02:48:47.163Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T21:00:00.995365487Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-16T02:46:03.497002+00:00
MacroGenics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 1.46 | 363.4% | 51.0% | |||
| 25Δ | 1.69 | 290.7% | 40.6% | |||
| 30Δ | 1.92 | 218.0% | 30.3% | |||
| 35Δ | ||||||
| 40Δ | ||||||
| 45Δ | 3.25 | 244.9% | 63.4% | |||
| 50Δ | 2.84 | 210.4% | 45.0% | |||
| 55Δ | 2.61 | 185.7% | 35.3% | |||
| 60Δ | 2.38 | 160.9% | 25.7% | |||
| 65Δ | 2.16 | 136.2% | 16.0% | |||
| 70Δ | ||||||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.46
- IV
- 363.4%
- B/E move
- 51.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.69
- IV
- 290.7%
- B/E move
- 40.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.92
- IV
- 218.0%
- B/E move
- 30.3%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 3.25
- IV
- 244.9%
- B/E move
- 63.4%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 2.84
- IV
- 210.4%
- B/E move
- 45.0%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 2.61
- IV
- 185.7%
- B/E move
- 35.3%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 2.38
- IV
- 160.9%
- B/E move
- 25.7%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 2.16
- IV
- 136.2%
- B/E move
- 16.0%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 119.68% | |
| 108.73% | |
| 105.01% | |
| 107.16% | |
| 176.76% | |
| 129.05% |
Biotechnology
MGTX
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New…
More →MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver…
More →MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular drugs. The company is headquartered in Montral,…
More →MLTX
MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to advancing therapies for chronic inflammatory diseases through its proprietary drug delivery…
More →MLYS
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. The…
More →MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United…
More →